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ABSTRACT Inspite of several stimulating developments
in gene therapy, the formulation of a targeted gene delivery
‘‘vector’’ is still far from ideal. We have demonstrated the
potential of reconstituted Sendai viral envelopes containing
only the fusion glycoprotein (F-virosomes) in targeted delivery
of reporter genes to liver cells of BALB/c mouse in vivo. The
membrane fusion-mediated high efficiency of gene transfer to
liver cells was ascertained following a critical evaluation of the
level of the DNA, mRNA, and relevant proteins. Furthermore,
the involvement of viral glycoprotein both as a unique natural
ligand and as a membrane fusogen could lead to preferential
transfection of parenchymal cell types of liver. The integration
of transgenes in the mouse chromosomal DNA and its stable
expression up to 4 mo after single i.v. administration of this
gene carrier has bolstered its efficiency and novelty. More-
over, the F-virosomes did not elicit significant humoral im-
mune response against the fusion protein in the injected
animal. The findings reported here open up the possibility for
considering ‘‘F-virosomes’’ as a promising ‘‘vehicle’’ for site-
specific DNA delivery in gene therapy.
Despite improvements in viral and nonviral vector systems for
gene therapy, current clinical trials have had limited success
mainly due to inadequacies of the DNA delivery system (1). To
overcome the problems associated with these vectors, we have
focused our attempts on the development of an engineered
Sendai viral envelope¶ (F-virosome) that is, in essence, a
hybrid vector between viral and nonviral strategies. Our find-
ings of the specific interaction of Sendai viral fusion glyco-
protein (F) with the human asialoglycoprotein receptor
(ASGP-R) is of considerable importance for the development
of safe and efficient hepatotropic vectors coveted for in vivo
liver gene therapy applications (2, 3, 4). Based on interaction
with ASGP-R, viral and nonviral hepatotropic gene transfer
systems have been used both in vitro and in vivo. Although
partial targeting to hepatocytes was achieved, the efficiency of
these vectors was found to be severely impeded because of the
lysosomal degradation of endocytosed ligands (5, 6, 7). Inter-
estingly, in case of F-virosomes, the F protein acts in a
bifunctional way, i.e., binding to hepatocytes followed by
membrane fusion-mediated direct release of the virosomal
aqueous contents to the cytoplasm of target cells (2). Having
recently established F-virosome-mediated efficient delivery of
foreign genes specifically into human hepatoblastoma cells in
culture (3), we assessed the ability of DNA-loaded F-virosomes
to affect targeted gene expression in mice after tail vein
injection.
MATERIALS AND METHODS
Plasmids. The plasmid, pCIS3CAT containing chloram-
phenicol acetyl transferase (CAT) gene under the control of
cytomegalovirus promoter, was constructed as described (3).
Plasmid, pBVluc (6.38 kb), containing the firefly luciferase
gene under control of cytomegalovirus promoter, was derived
from pCEP4-X2 luc (Stratagene). In pBVluc, the luciferase-
coding sequence is followed by SV40 polyadenylation se-
quence. These plasmids were isolated using Qiagen Megaprep
kit (Chatsworth, CA).
Preparation of DNA Loaded F-Virosomes. The F-virosomes
containing pCIS3CAT or pBVluc DNA were reconstituted as
described earlier. (3). In brief, 75 mg of each plasmid was
incubated with detergent solubilized fraction of Sendai virus
containing its envelope devoid of hemagglutinin-neuramini-
dase (HN) protein. Finally, F-virosomes containing the DNA
were prepared by stepwise removal of the detergent by using
SM2 biobeads (Bio-Rad). Heat-treatment of loaded F-
virosomes was carried out at 56°C for 30 min.
Administration of Loaded F-Virosomes and Gene Expres-
sion in Vivo. Twelve-week-old female BALB/c mice ('18 g)
were injected i.v. into the tail vein, with DNA-loaded F-
virosomes (0.4 mg F protein containing 2 mg of DNA) in a final
volume of 0.2 ml Tris-buffered saline (3) containing 2 mM
Ca12. Antibody response against F protein was checked as
described earlier (8). (i) Reverse transcription–PCR (RT-
PCR) amplification of CAT-specific transcripts: 100 mg of total
RNA isolated (9) from liver was incubated with 10 units of
DNase I (Sigma) at 37°C for 15 min, and 1 mg of this RNA was
reverse transcribed with 200 units of Moloney murine leuke-
mia virus-reverse transcriptase (GIBCO/BRL). CAT-specific
transcripts were amplified by 35 cycles of RT-PCR (1 min at
94°C, 1 min at 60°C, 1 min at 72°C, and final extension, 1 min
at 72°C) by using the antisense primer 59-TTA CGC CCC GCC
CTG CCA-39 from the 39 end of CAT and the sense strand
primer, 59-ACC GTT GAT ATA TCC CAA TGG-39, from a
sequence 27 nucleotides downstream of the 59 end of CAT.
The RT-PCR products were electrophoresed on 1.2% agarose
gel and transferred to nylon membrane. A 1.5-kb XhoI/SmaI
CAT gene fragment derived from the plasmid pCIS3CAT was
labeled with [a-32P ]dCTP by using random primer-labeling
technique. The above blots were subsequently hybridized with
this probe. (ii) Detection of CAT protein by ELISA: subcel-
lular fractionation of various organs was carried out as de-
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scribed (2). In brief, the organs were placed in isotonic
homogenizing buffer (0.01 M TriszHCl (pH 7.4) containing
0.25 M sucrose) and then dispersed in Potter–Elvehjem type
homogenizer at 4°C. The cytosolic fraction was purified after
differential centrifugation of the homogenate. The amount of
CAT protein expressed in the cytosolic fraction was quanti-
tated using the CAT ELISA kit (Boehringer Mannheim).
Detection of CAT Gene in Liver Parenchymal Cells by PCR.
Parenchymal cell (hepatocyte) separation was carried out
following a standard procedure (10). To summarize, the
perfused liver was excised from the animal, cut into small
pieces, and washed thoroughly. The liver pieces were incubated
at 37°C for 15 min in Collagenase A- (Boehringer Mannheim)
containing buffer. The resulting liver mass was filtered through
a nylon mesh, and the filtrate was centrifuged at 400 rpm for
10 min at 4°C to obtain the pellet-containing hepatocytes. The
supernatant containing non-hepatocytes was treated with
0.2% pronaseE (Sigma) to digest the contaminating hepato-
cytes completely (11). The non-hepatocyte pellet was obtained
by centrifuging the pronase-treated supernatant at 1,300 rpm
for 10 min at 4°C. Both of these cell types were washed three
times with ice-cold PBS containing 5 mM EDTA, and the cell
pellets were processed for subcellular fractionation as de-
scribed above. One microgram of total DNA isolated (9) from
each subcellular fraction was subjected to PCR by using 1.25
units of AmpliTaq DNA polymerase (Perkin–Elmer). A
633-bp fragment of CAT gene was amplified by 35 cycles of
PCR (using the conditions mentioned above). The PCR prod-
ucts were visualized on a 1.2% agarose gel.
Measurement of Luciferase Activity in Parenchymal and
Nonparenchymal Liver Cells 24 h After Injection of pBVluc
Loaded F-Virosomes. After separation, these cells were
washed twice with Tricine-buffered saline and suspended in
the same. For luciferase assay, the Triton X-100 solubilized cell
lysate (from 1 3 107 cells) was mixed with luciferase assay
buffer containing 1 mM luciferin (Boehringer Mannheim)
(12). Luciferase activity (in mV) was measured in a 1250
Luminometer (BIO-Orbit, Finland) as described earlier (13).
State of Targeted DNA Associated with Persistent Gene
Expression. Total DNA was extracted from parenchymal cells,
1, 15, 30, and 60 days after injection. The chromosomal DNA
was separated from episomal DNA by gel filtration using
Sephacryl S-1000 beads (14). Both the DNA fractions were
ethanol precipitated and finally dissolved in TE buffer (10 mM
TriszHCl and 1 mM EDTA, pH 8.0). The chromosomal DNA
was made free of any contaminating episomal DNA by elec-
trophoresis on a 1% low melting point agarose gel (9). After
electrophoresis of the chromosomal DNA (undigested) on
0.7% agarose gel, the blots were hybridized with 1.5-kb CAT
gene fragment. Purified chromosomal DNA digested with
various restriction enzymes (New England Biolabs) was hy-
bridized as described above. The chromosomal and episomal
fractions were analyzed by PCR using CAT-specific primers.
The PCR cycles were as follows: initial denaturation, 94°C for
10 min; denaturation, 94°C for 1 min; annealing, 60°C for 1
min; extension, 72°C for 1 min; and final extension, 72°C for 10
min. After 35 cycles, the products were electrophoresed on
1.2% agarose gel and transferred to nylon membrane, and the
blot was hybridized with 1.5-kb CAT gene fragment.
RESULTS
CAT Gene Expression in Vivo After Administration of
DNA-Loaded F-Virosomes. The CAT gene expression was
FIG. 1. CAT gene is expressed in a dose-dependent fashion. Livers
from injected mice were subjected to subcellular fractionation 24 h
after injection, and the amount of CAT protein expressed per milli-
gram of cytosolic protein was determined by CAT ELISA. Each point
is an average of four animals.
FIG. 2. Tissue-specific expression of CAT gene 24 h after injection.
(A) RT-PCR amplification of CAT mRNA from various organs using
CAT-specific primers followed by hybridization with 1.5-kb-labeled
CAT gene probe. Lanes 1, 2, 3, and 4 show RT-PCR products from
liver, lung, kidney, and spleen, respectively; Lanes 19–49, correspond-
ing samples from mice injected with heat-treated loaded F-virosomes;
Lanes 199–499, corresponding samples from mice injected with free
DNA. Positions of 1-kb ladder (GIBCO/BRL) is shown on left. (B)
The amount of CAT protein in cytosolic extracts of various organs was
determined by CAT ELISA. Each point represents mean value (6 SD)
from three animals. E, experimental; HC, heat control; FD, free DNA.
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assessed both at the level of mRNA and of protein. Maximum
CAT expression was achieved in the liver at a dose of 2 mg of
DNA loaded in F-virosomes (Fig. 1). RT-PCR analysis of total
RNA from various organs confirmed the presence of CAT-
specific transcripts in mouse liver (Fig. 2A). Other organs
analyzed, i.e., lung, kidney, and spleen, did not express signif-
icant CAT transcripts except a very faint RT-PCR signal in
case of lungs. CAT gene expression was not detected in tissues
like heart, muscle, brain, lymph nodes, skin, and tail. Heat-
treated virosomes and the free DNA controls also did not
exhibit any CAT-specific transcripts. The relative expression of
CAT protein in the liver was comparable with mRNA levels by
using the same category of F-virosomes (Fig. 2B).
The expression of both mRNA and protein in mouse liver
persisted over a period of 60 days (Fig. 3 A and B), pointing to
the overall efficiency of this delivery system. The expression
also was detected until 120 days (Fig. 3B) with no F-specific
humoral antibody response from 10 days onward (Fig. 3C).
Moreover, the animals remained healthy and active during the
experiments.
Fusion-Mediated Uptake of pCIS3CAT DNA by Liver Pa-
renchymal Cells. Experiments were designed to determine the
cellular localization of the input DNA. Total DNA from
various subcellular fractions of these cells was analyzed by PCR
using CAT-specific primers, that amplify a 633-bp fragment of
CAT gene. After 2 h after injection of loaded F-virosomes,
plasmid DNA was detected only in the cytosolic fraction (Fig.
4). After 6 h, majority of the DNA was localized in the nucleus
and was detected mainly in this compartment until 24 h. No
DNA was detected in the lysosomal/mitochondrial fraction at
any time point after injection. In case of the corresponding
heat-treated virosomes, the delivered DNA persisted mainly in
the lysosomal/mitochondrial fraction until 12 h and finally
could not be detected in any fraction after 24 h. PCR-amplified
product was not detected from any subcellular fraction of
non-parenchymal cells or after injection of free DNA.
Cell Type-Specific Luciferase Gene Expression in Mouse
Liver. The luciferase activity was found to be 8–10 times
greater in parenchymal cells compared with the non-
parenchymal counterparts. Moreover, the luciferase expres-
sion in parenchymal cells from experimental mice was 3–4
times more than that of the corresponding heat controls. In
case of non-parenchymal cells, experimental and heat control
exhibited little difference in luciferase activity (Fig. 5). The
purity of the cell preparations was monitored by pronase
susceptibility and glass slide attachment of the non-
parenchymal cells (15).
Integration of the Delivered DNA in the Chromosome of
Hepatocytes. To determine the state of targeted DNA in
hepatocytes after administration of loaded F-virosomes, pu-
rified chromosomal DNA was hybridized to labeled 1.5-kb
CAT gene fragment derived from pCIS3CAT. No hybridiza-
tion signal was detected from purified chromosomal DNA 1
day after injection; however, chromosomal DNAs from hepa-
tocytes 15, 30, and 60 days after injection, contained high
molecular weight sequences that hybridized with the CAT gene
probe (Fig. 6A). Chromosomal DNA from mock-injected mice
and Herring sperm DNA (GIBCO/BRL) and DNA from
non-parenchymal cells failed to show any hybridization signal.
To establish the nature of integration of the DNA in mouse
chromosome, purified genomic DNA from mouse liver 60 days
after injection, was digested with various sets of restriction
enzymes and the resulting fragments were analyzed after
hybridization with 1.5-kb CAT gene probe. Purified chromo-
somal DNA, isolated from CAT-injected animals and re-
stricted with different sets of enzymes, generated CAT-
positive fragments of lower size than that of the linearized
plasmid (6.7 kb) and a few hybridizable fragments greater in
size than the linearized plasmid (Fig. 6B).
Because these band patterns do not correspond to those
obtained after digestion of pCIS3CAT (data not shown), this
suggests the possibility of random integration of the delivered
plasmid in the mouse chromosome. The integration status was
further confirmed by PCR analysis of the purified chromo-
somal and episomal fractions by using CAT-specific primers.
Twenty four hours after injection, amplified CAT gene frag-
ment (633 bp) was detected only from the episomal fraction
but no such product was obtained from the corresponding
chromosomal fractions. On the other hand, 15, 30, and 60 days
FIG. 3. Persistent expression of CAT gene in mouse liver and
analysis of humoral immune response against the injected F-
virosomes. (A) RT-PCR amplification of CAT transcripts at various
time intervals after injection. The different lanes are: lane 1, 633-bp
CAT gene fragment amplified from pCIS3CAT; lanes 2–10, RT-PCR
products from experimental mice at 0.25, 1, 2, 4, 6, 8, 15, 30, and 60
days after injection; lanes 11–19, the corresponding heat controls. (B)
CAT expression was quantitated in cytosolic fractions of liver cells by
CAT ELISA. Each value represents mean (6 SD) from three animals.
(C) Western blot analysis of sera from F-virosome-injected mice.
BALB/c mice were injected with loaded F-virosomes (600 mg F
protein), and serum was prepared at different time points after
injection. Sendai virus (10 mg) was resolved on a 10% SDS/PAGE gel
under nonreducing conditions and visualized by Western blotting with
rabbit anti Sendai antibodies (lane 1) and sera from mice 10, 15, 30,
and 60 days after injection (lanes 2–5). At 60 days after injection, a
booster dose of F-virosomes was given, and lane 6 represents serum
isolated after 2-mo interval.
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after injection, amplified products were detected only from the
chromosomal fractions but not from the corresponding epi-
somal fractions. The possibility of nonspecific PCR amplifi-
cation was ruled out from appropriate negative controls (Fig.
6C). The copy number of the plasmid integrated in the genome
was found to range from '100 to 300 copies per cell as
calculated from slot blot hybridization of chromosomal DNA
from hepatocytes 60 days after injection.
DISCUSSION
The art of natural ligand-receptor interaction and Sendai viral
F glycoprotein-catalyzed membrane fusion has been exploited
in the construction of a safe and efficient vehicle (F-virosome)
for site-specific gene delivery to mouse liver cells in vivo. The
F glycoprotein is known to possess Lex- (Galb1–4[Fuca1–
3]GlcNAc-) terminated biantennary oligosaccharides (16).
The Lex moiety possesses much higher affinity for ASGP-R
present on hepatocytes. This property is considered to be a
prerequisite of targeted delivery systems (17). The liver is an
ideal organ for transfection of a gene whose product is secreted
into the circulation and is important for systemic gene therapy
for several inherited diseases. Moreover, the nonpathogenicity
of Sendai virus to humans and its little immunogenicity have
together increased the prospects of F-virosomes in gene ther-
apy (18, 19). The results presented here by using two reporter
genes independently are highly supportive of this notion.
It has been shown earlier that heat-treated loaded F-
virosomes deliver genes to the lysosomal compartment of the
cell after the receptor-mediated route of entry (3). The higher
efficiency of fusion-mediated delivery over receptor-mediated
entry is very much pronounced below 3 mg of DNA dose (Fig.
1). The hepatotrotopic nature of this gene carrier is revealed
clearly both in terms of mRNA (Fig. 2A) and protein levels
(Fig. 2B). More striking is the sustained nature of gene
expression (Fig. 3 A and B). These features represent a
instance of targeted and stable gene expression in vivo with no
detectable adverse immune effects (Fig. 3C). Recently, at-
tempts have been made to use liganded cationic-liposomes for
transgene expression in vivo. Besides the known risk of toxicity
of cationic lipids and the transient expression of CAT gene, the
efficiency of this system is '10–12 times less (20) than that of
the F-virosomal delivery. In spite of a sustained insulin gene
expression through Sendai virus-liposome complex, this sys-
tem lacks cell-type specificity and may have undesirable side
effects because of the presence of the sialic acid-binding
protein (HN) of viral origin (19). The ‘‘Trojan Horse’’ strategy
of reconstituted Sendai virus envelope in the field of drug
delivery and gene therapy as reviewed earlier (21) also suffers
from the lack of target specificity. Moreover, attempts have
been made to deliver preproinsulin I gene through lactosyl-
ceramide containing liposomes in vivo. These vesicles are
known to be internalized through ASGP-R on liver cells (11).
The transient expression (until 4 h) resulting from these
experiments corroborates with the endocytotic uptake of these
loaded liposomes (leading to the lysosomal degradation of the
transgene) in contrast to the fusion-mediated delivery through
F-virosomes. Besides this, the known Lex type of ligand present
on F-virosomes confers it with the added novelty of selective
targeting to selective cell types in vivo over the existing modes
of DNA targeting.
The F-virosome-mediated, targeted cytosolic gene delivery
in vivo to liver parenchymal cells is apprehended from the
cytosolic localization of plasmid DNA at 2 h after injection and
its absolute nuclear localization 6 h after injection onward (Fig.
FIG. 4. PCR amplification of the delivered DNA in various subcellular fractions of hepatocytes. Total DNA from various subcellular fractions
of parenchymal cells was analyzed by PCR using CAT primers. E, experimental; HC, heat control; FD, free DNA. The lanes are: N, nuclear; C,
cytosolic; and L, lysosomal/mitochondrial. The 633-bp CAT gene fragment amplified from pCIS3CAT was used as a control (1).
FIG. 5. Luciferase gene is preferentially expressed in parenchymal
cell types of mouse liver. Luciferase activity in parenchymal and
non-parenchymal cell types was determined as described in Material
and Methods. Values represent mean (6 SD) from four mice livers. E,
experimental; HC, heat control; FD, free DNA.
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4). This is additionally substantiated from the lysosomal lo-
calization of plasmid when delivered through heat-treated
F-virosomes (3). The overall efficiency of this delivery mode
also is reflected from the absence of any detectable PCR signal
upon i.v. administration of free DNA. This is probably the first
systematic demonstration of intracellular trafficking of a for-
eign gene administered in vivo. Another strong evidence of this
membrane fusion-mediated targeted gene delivery is the pref-
erential expression of luciferase gene in the parenchymal
cell-types of mouse liver (Fig. 5).
The persistent nature of transgene expression in hepatocytes
may be explained from the stable integration of CAT gene in
the mouse chromosome (Fig. 6). It is pertinent to note that
sustained gene expression does not appear to be affected by
the random nature of integration of pCIS3CAT DNA (Fig.
6B). The F-virosomes, being at the interface of viral and
nonviral vectors, are adequately safe in comparison to their
nonhybrid counterparts (1). These attributes highlight the
potential of this gene carrier for targeted delivery of thera-
peutic genes in vivo.
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FIG. 6. Integration status of CAT gene in liver parenchymal cells.
At different time points after injection, total DNA was isolated from
hepatocyte nuclei, and the chromosomal pool was purified from the
low molecular weight episomal fraction as described in Material and
Methods. (A) Southern hybridization of undigested chromosomal
DNA with labeled CAT gene probe. (B) Southern hybridization
pattern of chromosomal DNA (from a single mouse) digested with
various restriction enzymes. Lane 1, Linearized pCIS3CAT-XhoI
digest; lane 2, genomic DNA from mock-injected animals after EcoRI
digestion; lanes 3–6, genomic DNA from experimental animals 60 days
postinjection after digestion with EcoRI, PstI/PvuII, AluI/HindIII, and
XhoI, respectively. (C) PCR of purified chromosomal and episomal
fractions from liver nuclei by using CAT primers.
11890 Medical Sciences: Ramani et al. Proc. Natl. Acad. Sci. USA 95 (1998)
